INSM - Insmed Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
25.93
-0.11 (-0.42%)
As of 11:04AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close26.04
Open26.10
Bid25.97 x 900
Ask26.02 x 1800
Day's Range25.88 - 26.33
52 Week Range11.31 - 33.13
Volume165,461
Avg. Volume876,832
Market Cap2.263B
Beta (3Y Monthly)3.98
PE Ratio (TTM)N/A
EPS (TTM)-4.29
Earnings DateJul 31, 2019 - Aug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est42.78
Trade prices are not sourced from all markets
  • Markityesterday

    See what the IHS Markit Score report has to say about Insmed Inc.

    Insmed Inc NASDAQ/NGS:INSMView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for INSM with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on June 11. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding INSM are favorable, with net inflows of $2.18 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Is Insmed Incorporated (INSM) A Good Stock To Buy?
    Insider Monkey8 days ago

    Is Insmed Incorporated (INSM) A Good Stock To Buy?

    Is Insmed Incorporated (NASDAQ:INSM) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to work. […]

  • Insmed to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
    PR Newswire13 days ago

    Insmed to Present at the Goldman Sachs 40th Annual Global Healthcare Conference

    BRIDGEWATER, N.J., June 6, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Will Lewis, Chairman and Chief Executive Officer of Insmed, will present at the Goldman Sachs 40th Annual Global Healthcare Conference in Rancho Palos Verdes on Thursday, June 13, 2019 at 8:00 a.m. PDT. Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases.

  • Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    PR Newswire15 days ago

    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BRIDGEWATER, N.J., June 4, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 12 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company. In connection with the commencement of their employment, the employees received options on June 3, 2019 to purchase an aggregate 59,300 shares of Insmed common stock at an exercise price of $23.25 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.

  • Thomson Reuters StreetEvents17 days ago

    Edited Transcript of INSM earnings conference call or presentation 7-May-19 12:30pm GMT

    Q1 2019 Insmed Inc Earnings Call

  • Insmed Announces Closing of Public Offering of Common Stock
    PR Newswire26 days ago

    Insmed Announces Closing of Public Offering of Common Stock

    BRIDGEWATER, N.J., May 24, 2019 /PRNewswire/ -- Insmed Incorporated (INSM) today announced the closing of the previously announced public offering of its common stock. Insmed issued and sold in the public offering 9,615,385 shares of common stock, at a public offering price of $26.00 per share, resulting in gross proceeds of approximately $250.0 million. Insmed's net proceeds from the offering, after deducting estimated offering expenses and underwriting discounts and commissions, were approximately $235.5 million.  The underwriters have been granted 30-day options to purchase up to an additional 1,042,307 shares of common stock from Insmed and up to 400,000 shares of common stock from William H. Lewis, the Company's Chairman and Chief Executive Officer.

  • What Did Insmed Incorporated's (NASDAQ:INSM) CEO Take Home Last Year?
    Simply Wall St.28 days ago

    What Did Insmed Incorporated's (NASDAQ:INSM) CEO Take Home Last Year?

    In 2012 Will Lewis was appointed CEO of Insmed Incorporated (NASDAQ:INSM). This report will, first, examine the CEO...

  • Benzinga28 days ago

    The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 21) Array Biopharma Inc (NASDAQ: ARRY ) (announced positive ...

  • Insmed Announces Pricing of Public Offering of Common Stock
    PR Newswire28 days ago

    Insmed Announces Pricing of Public Offering of Common Stock

    BRIDGEWATER, N.J., May 21, 2019 /PRNewswire/ -- Insmed Incorporated (INSM) announced today that it priced a registered underwritten public offering of 9,615,385 shares of its common stock, at a price to the public of $26.00 per share before underwriting discounts and commissions. Gross proceeds from the offering of these shares, before deducting underwriting discounts and commissions, are expected to be approximately $250.0 million.  The underwriters have been granted 30-day options to purchase up to an additional 1,042,307 shares of common stock from Insmed and up to 400,000 shares of common stock from William H. Lewis, the Company's Chairman and Chief Executive Officer.

  • Benzinga29 days ago

    The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 20) Kaleido Biosciences Inc (NASDAQ: KLDO ) Down In The ...

  • Insmed Announces Proposed Public Offering of Common Stock
    PR Newswirelast month

    Insmed Announces Proposed Public Offering of Common Stock

    BRIDGEWATER, N.J., May 20, 2019 /PRNewswire/ -- Insmed Incorporated (INSM) announced today that it has commenced an underwritten public offering of up to $250 million of its common stock. In addition, Insmed intends to grant the underwriters a 30-day option to purchase up to an additional $25.5 million of its common stock at the public offering price, less the underwriting discounts and commissions. William H. Lewis, the Company's Chairman and Chief Executive Officer, intends to grant the underwriters a 30-day option to purchase up to $12 million of Insmed common stock held by Mr. Lewis also at the public offering price.

  • New Phase 3 Data Show Sustainability and Durability of Culture Conversion with ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with Refractory MAC Lung Disease
    PR Newswirelast month

    New Phase 3 Data Show Sustainability and Durability of Culture Conversion with ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with Refractory MAC Lung Disease

    BRIDGEWATER, N.J., May 20, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today presented new data from the ongoing Phase 3 CONVERT study of ARIKAYCE® (amikacin liposome inhalation suspension) in patients with refractory Mycobacterium avium complex (MAC) lung disease, demonstrating that the addition of ARIKAYCE to guideline-based therapy (GBT) was associated with sustained culture conversion through the end of treatment as well as durable culture conversion three months post-treatment compared with GBT alone.

  • Insmed (INSM) Q1 2019 Earnings Call Transcript
    Motley Foollast month

    Insmed (INSM) Q1 2019 Earnings Call Transcript

    INSM earnings call for the period ending March 31, 2019.

  • Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates
    Zackslast month

    Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates

    Insmed (INSM) delivered earnings and revenue surprises of 0.00% and 0.01%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Insmed: 1Q Earnings Snapshot

    On a per-share basis, the Bridgewater, New Jersey-based company said it had a loss of 96 cents. Losses, adjusted for amortization costs, were 94 cents per share. The results met Wall Street expectations. ...

  • Insmed Reports First Quarter 2019 Financial Results and Provides Business Update
    PR Newswirelast month

    Insmed Reports First Quarter 2019 Financial Results and Provides Business Update

    -- ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Net Product Sales $21.0 Million for the First Quarter of 2019 -- -- Company Raises Full-Year 2019 ARIKAYCE Revenue Guidance to Range of $90 Million ...

  • Did Hedge Funds Drop The Ball On Insmed Incorporated (INSM) ?
    Insider Monkey2 months ago

    Did Hedge Funds Drop The Ball On Insmed Incorporated (INSM) ?

    We at Insider Monkey have gone over 700 13F filings that hedge funds and prominent investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of December 31st. In this article we look at what those investors think of Insmed Incorporated (NASDAQ:INSM). Is Insmed Incorporated (NASDAQ:INSM) […]

  • Top Ranked Momentum Stocks to Buy for May 1st
    Zacks2 months ago

    Top Ranked Momentum Stocks to Buy for May 1st

    Top Ranked Momentum Stocks to Buy for May 1st

  • Insmed to Host First Quarter 2019 Financial Results Conference Call on Tuesday, May 7, 2019
    PR Newswire2 months ago

    Insmed to Host First Quarter 2019 Financial Results Conference Call on Tuesday, May 7, 2019

    BRIDGEWATER, N.J., April 30, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first quarter 2019 financial results on Tuesday, May 7, 2019. Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Tuesday, May 7, 2019 to discuss the financial results and provide a business update. Shareholders and other interested parties may participate in the conference call by dialing (888) 317-6003 (domestic) or (412) 317-6061 (international) and referencing conference ID number 6243203.

  • Estimating The Intrinsic Value Of Insmed Incorporated (NASDAQ:INSM)
    Simply Wall St.2 months ago

    Estimating The Intrinsic Value Of Insmed Incorporated (NASDAQ:INSM)

    How far off is Insmed Incorporated (NASDAQ:INSM) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the foreast future cash flows of the company and dis...

  • Insmed Granted Additional U.S. Patent For ARIKAYCE® (amikacin liposome inhalation suspension), Strengthening Brand's Global Patent Portfolio
    PR Newswire2 months ago

    Insmed Granted Additional U.S. Patent For ARIKAYCE® (amikacin liposome inhalation suspension), Strengthening Brand's Global Patent Portfolio

    BRIDGEWATER, N.J., April 9, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued patent No. 10,251,900 for certain uses of ARIKAYCE (amikacin liposome inhalation suspension). The claims of the patent relate in part to methods for treating Mycobacterium avium complex (MAC) lung disease via administration of ARIKAYCE to patients previously unresponsive to MAC therapy. This is the 10th patent issued by the USPTO for ARIKAYCE in MAC lung disease and the second with an expiry date of May 15, 2035.

  • Insmed Provides Update on ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Launch
    PR Newswire2 months ago

    Insmed Provides Update on ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Launch

    BRIDGEWATER, N.J., April 8, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today provided an update on the U.S. launch of ARIKAYCE® (amikacin liposome inhalation suspension), including preliminary net product sales for the first quarter of 2019.  ARIKAYCE was granted accelerated approval by the U.S. Food and Drug Administration (FDA) on September 28, 2018, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients who have limited or no alternative treatment options. "We continue to be very pleased with the U.S. launch progress of ARIKAYCE and the positive feedback received from the refractory MAC lung disease community," said Will Lewis, Chairman and Chief Executive Officer of Insmed.